Aktis Oncology, Inc. (AKTS) vs Pacira BioSciences, Inc. (PCRX)
A side-by-side comparison of Aktis Oncology, Inc. and Pacira BioSciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AKTS
Aktis Oncology, Inc.
$18.06HealthcareDelayed quote: Oct 6, 2026, 1:20 PM EDT
PCRX
Pacira BioSciences, Inc.
$24.75HealthcareDelayed quote: Oct 6, 2026, 1:14 PM EDT
Total return — AKTS vs PCRX
growth of $100 · dividends reinvested · last 1yAKTS -17.3% (-17.3%/yr)PCRX -1.0% (-1.0%/yr)PCRX compounded faster over this window
AKTS PCRX
AKTS vs PCRX: by the numbers
- •PCRX is the larger company ($973M vs $964M market cap).
- •PCRX is profitable (1.96% net margin) while AKTS runs a net loss (-727.04%).
Metrics side by side
Valuation
| Metric | AKTS | PCRX |
|---|---|---|
| P/E ratio | N/A | 70.44 |
| P/S ratio | 95.87 | 1.30 |
| P/B ratio | 1.99 | 1.45 |
| EV / EBITDA | N/A | 11.39 |
| FCF yield | N/A | 18.44% |
Profitability
| Metric | AKTS | PCRX |
|---|---|---|
| Gross margin | 100.00% | 79.21% |
| Operating margin | -1149.52% | 2.47% |
| Net margin | -727.04% | 1.96% |
| ROE | -15.09% | 2.18% |
| ROIC | -16.54% | 1.35% |
Growth (annualized)
| Metric | AKTS | PCRX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 8.20% |
| EPS CAGR (5Y) | N/A | -45.77% |
| FCF CAGR (5Y) | N/A | 16.72% |
| Total return CAGR (5Y) | N/A | -12.27% |
Frequently asked
- Is AKTS or PCRX more profitable?
- PCRX runs the higher net margin — AKTS at -727.04% versus PCRX at 1.96%.
Go deeper
Dig into the metrics
Pacira BioSciences P/E ratioAktis Oncology ROEPacira BioSciences ROEAktis Oncology operating marginPacira BioSciences operating marginAktis Oncology revenue growthPacira BioSciences revenue growthAktis Oncology free cash flowPacira BioSciences free cash flow
Aktis Oncology & Pacira BioSciences appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.